Compare Amylx Pharmaceuticals Inc (AMLX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Amylx Pharmaceuticals Inc trades at $23.47 (market cap $2.64B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. Which is the better fit depends on your goals.
| AMLX | QQQE | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $24.19 | $122.72 |
52-Week Low | $7.82 | $96.06 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
QQQE trades at $123.25, up 0.9% on the day, with a bullish technical signal from moving averages but a neutral oscillator reading. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk in top holdings like tech giants. Recent news highlights its appeal as a defensive play amid the Nasdaq rally, with SpaceX's imminent inclusion potentially driving inflows.
The outlook remains positive given structural diversification benefits and growth exposure, though overbought RSI levels near 79 suggest near-term caution. Risks include market volatility and tech sector sensitivity, but analyst sentiment favors QQQE over market-cap-weighted peers for balanced Nasdaq participation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
